Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0XNZEO
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
WO2020252015A1 ADCLP-16
|
|||||
| Synonyms |
ADCLP-16
Click to Show/Hide
|
|||||
| Organization |
SUTRO BIOPHARMA, INC.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
1-10
|
|||||
| Structure |
|
|||||
| Antibody Name |
mAb42
|
Antibody Info | ||||
| Antigen Name |
Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)
|
Antigen Info | ||||
| Payload Name |
Exatecan
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
DBCO-4,4nnAA-PEG-VKG
|
Linker Info | ||||
| Conjugate Type |
Conjugation through Dibenzocyclooctyne
|
|||||
| Combination Type |
DBCO-4,4nnAA-PEG-VKG-Exatecan
|
|||||